An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
IPA (ImmunoPrecise Antibodies Ltd.) to host an earnings conference call to discuss third fiscal year 2024 results and recent business highlights. The conference call will take place on March 14, 2024, at 10:30 am Eastern Time. ImmunoPrecise Antibodies Ltd. is an artificial intelligence-driven biotherapeutic research and technology company with subsidiaries in North America and Europe. The company leverages systems biology, multi-omics modeling, and complex AI systems for bioplatform-based antibody discovery.
Positive
None.
Negative
None.
The Company to host an earnings conference call via webcast.
VICTORIA, British Columbia--(BUSINESS WIRE)--
IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for third fiscal year 2024, on Thursday, March 14, 2024, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call.
ImmunoPrecise management will host the conference call followed by a question-and-answer period.
Conference Call and Webcast Details
The Company will host a live conference call and webcast to discuss these results and provide a corporate update on Thursday, January 14, 2024, at 10:30AM ET.
Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization.
Anyone listening to the call is encouraged to read the company's periodic reports available on the company’s profile at www.sedarplus.com and www.sec.gov, including the discussion of risk factors and historical results of operations and financial condition in those reports.
ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA Family”). The IPA Family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. Services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. For further information, visit www.ipatherapeutics.com.
When will IPA host the earnings conference call to discuss third fiscal year 2024 results?
IPA will host the earnings conference call on March 14, 2024, at 10:30 am Eastern Time.
What is the focus of the conference call hosted by IPA?
The conference call will discuss the quarterly results and recent business highlights for the third fiscal year 2024.
What technologies does ImmunoPrecise Antibodies Ltd. leverage for bioplatform-based antibody discovery?
ImmunoPrecise Antibodies Ltd. leverages systems biology, multi-omics modeling, and complex artificial intelligence systems for bioplatform-based antibody discovery.
What are some subsidiaries of ImmunoPrecise Antibodies Ltd. in North America and Europe?
Some subsidiaries of ImmunoPrecise Antibodies Ltd. include Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd., and ImmunoPrecise Antibodies (Europe) B.V.
